Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.

Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther (2017) 0.75

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet (2010) 3.55

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost (2007) 3.38

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med (2014) 2.69

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J (2009) 1.92

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J (2010) 1.25

Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA (2011) 1.19

Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health (2010) 1.03

Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Neth Heart J (2014) 1.00

Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J (2015) 0.98

High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91

CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv (2012) 0.87

Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83

Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J (2015) 0.82

Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther (2011) 0.81

P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Cardiol Res Pract (2013) 0.79

Charcot-Leyden crystals in acute myeloid leukemia. Int J Lab Hematol (2015) 0.75